Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
ID: 350921Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350921

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-062.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting proposals for the Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional) grant opportunity. This initiative aims to advance translational research that addresses the public health burden of substance use through innovative studies that may begin without preliminary data, utilizing a phased approach for planning and implementation. The program encourages community engagement and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of the review process. Funding amounts are capped at $350,000 per year for the R61 phase and $750,000 for the R33 phase, with applications due by February 14, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-062.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-062-Full-Announcement.html
    PAR-24-062.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is inviting proposals for the R61/R33 funding opportunity aimed at advancing research on substance use epidemiology, prevention, and services. This phased award encourages innovative research that bridges between different disciplines and emphasizes community engagement in treatment and prevention. Applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP), crucial in the review process. The program encourages projects with no preliminary data, promoting a phased approach (R61 for planning and R33 for larger studies), with a maximum funding limit of $350,000 per year for R61 and $750,000 for R33. Applications are due by February 14, 2024. The NIH will evaluate based on significance, investigator qualifications, innovation, and approach, focusing on addressing health disparities and scaling effective interventions. The opportunity aims to reduce the burden of substance use on public health through robust, actionable research that informs real-world practices and policies.
    Similar Opportunities
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials," aimed at encouraging pilot research to develop and test interventions that prevent or delay substance use. The initiative focuses on the creation and pilot testing of new or adapted strategies to curb substance misuse, particularly among underserved populations, while also addressing related negative outcomes such as impaired driving and transmission of infectious diseases. Eligible applicants include a wide range of institutions, such as academic, nonprofit, and government organizations, with funding available up to $450,000 over three years. Interested parties should note that applications are due starting January 16, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-25-078), aimed at supporting research that transforms addiction treatment and care to combat the ongoing overdose crisis. This initiative encourages phased applications (R61/R33), where the R61 phase focuses on exploratory activities without the need for existing pilot data, while the R33 phase seeks to implement larger studies based on successful R61 milestones, emphasizing stigma-free and patient-centered approaches. With up to $10 million allocated for FY2026 and a maximum award period of six years, applicants must include a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity, and applications are to be submitted through Grants.gov by the closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders" (R34 Clinical Trial Optional). This initiative encourages pilot studies aimed at preparing for larger-scale effectiveness trials that focus on optimizing access, quality, and affordability of substance use disorder treatments and related services, with an emphasis on diverse perspectives through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $450,000 in direct costs for a three-year grant, with application due dates beginning January 16, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-100.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data," aimed at supporting innovative analyses of existing datasets related to substance use behaviors, including alcohol, tobacco, and illicit drugs, and their connections to health outcomes such as HIV. This grant, classified as an R21 Clinical Trial Not Allowed, encourages applicants to utilize existing social science, behavioral, administrative, and neuroimaging data to enhance understanding of drug use behaviors, their consequences, and effective prevention and treatment strategies. A total of $2 million is available for projects over a two-year period, with individual application budgets capped at $275,000. Interested applicants must submit their proposals electronically through Grants.gov by December 3, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), a federal grant opportunity aimed at funding research for developing and testing behavioral treatments for substance use and dependence. This initiative seeks to encourage research that tests the efficacy of behavioral interventions, examines mechanisms of behavior change, and optimizes treatment approaches, particularly for individuals with comorbidities and those in drug abuse treatment. The program is crucial for advancing substance abuse treatment and addressing health disparities, with a maximum funding amount of $450,000 available over three years. Interested applicants, including various educational institutions and community organizations, must submit their proposals by March 21, 2025, and can find additional information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.